Journal article

Building the case for the calcitonin receptor as a viable target for the treatment of glioblastoma

Pragya Gupta, Sebastian GB Furness, Lucas Bittencourt, David L Hare, Peter J Wookey

Therapeutic Advances in Medical Oncology | SAGE PUBLICATIONS LTD | Published : 2020


Researchers are actively seeking novel targeted therapies for the brain tumour glioblastoma (GBM) as the mean survival is less than 15 months. Here we discuss the proposal that the calcitonin receptor (CT Receptor), expressed in 76-86% of patient biopsies, is expressed by both malignant glioma cells and putative glioma stem cells (GSCs), and therefore represents a potential therapeutic target. Forty-two per cent (42%) of high-grade glioma (HGG; representative of GSCs) cell lines express CT Receptor protein. CT Receptors are widely expressed throughout the life cycle of organisms and in some instances promote apoptosis. Which of the common isoforms of the CT Receptor are predominantly express..

View full abstract


Awarded by ARC

Funding Acknowledgements

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: SGBF is an ARC Future Fellow (FT180100543).